- Home
- CMA vs CORT Comparison
CMA vs CORT Comparison
Compare CMA & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- CORT
- Stock Information
- Founded
- CMA 1849
- CORT 1998
- Country
- CMA United States
- CORT United States
- Employees
- CMA N/A
- CORT N/A
- Industry
- CMA Major Banks
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- CMA Finance
- CORT Health Care
- Exchange
- CMA Nasdaq
- CORT Nasdaq
- Market Cap
- CMA 7.7B
- CORT 7.5B
- IPO Year
- CMA N/A
- CORT N/A
- Fundamental
- Price
- CMA $63.70
- CORT $71.72
- Analyst Decision
- CMA Hold
- CORT Strong Buy
- Analyst Count
- CMA 22
- CORT 4
- Target Price
- CMA $61.57
- CORT $142.00
- AVG Volume (30 Days)
- CMA 1.5M
- CORT 1.6M
- Earning Date
- CMA 07-18-2025
- CORT 07-28-2025
- Dividend Yield
- CMA 4.48%
- CORT N/A
- EPS Growth
- CMA 4.95
- CORT 8.36
- EPS
- CMA 5.29
- CORT 1.14
- Revenue
- CMA $3,234,000,000.00
- CORT $685,446,000.00
- Revenue This Year
- CMA $7.26
- CORT $35.83
- Revenue Next Year
- CMA $2.83
- CORT $35.24
- P/E Ratio
- CMA $12.00
- CORT $62.92
- Revenue Growth
- CMA N/A
- CORT 30.93
- 52 Week Low
- CMA $48.12
- CORT $30.77
- 52 Week High
- CMA $73.45
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- CMA 68.60
- CORT 50.50
- Support Level
- CMA $62.38
- CORT $66.49
- Resistance Level
- CMA $64.08
- CORT $72.49
- Average True Range (ATR)
- CMA 1.24
- CORT 2.85
- MACD
- CMA 0.45
- CORT -0.09
- Stochastic Oscillator
- CMA 94.48
- CORT 49.95
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.